NFEPP

NFEPP is a fluorinated derivative of the opioid fentanyl, but unlike most opioids, it has been designed to relieve pain without causing significant side effects. This is achieved by targeting inflamed tissues only, leaving healthy tissues unaffected.

Mechanism of Action

NFEPP binds to the mu-opioid receptor in a pH-dependent manner. In inflamed tissues, the environment is more acidic, which allows NFEPP to bind more effectively. This selective binding reduces the risk of side effects commonly associated with opioids, such as respiratory depression, constipation, and addiction.

Development

NFEPP was developed by a team of researchers at the University of Munich. The team was led by Dr. Christoph Stein, who has been researching non-addictive painkillers for several years. The development of NFEPP represents a significant breakthrough in the field of pain management.

Clinical Trials

As of 2017, NFEPP is still in the preclinical stage of development. Animal studies have shown promising results, but human trials have not yet begun. The researchers are hopeful that NFEPP will prove to be a safe and effective treatment for chronic pain.

Potential Impact

If successful, NFEPP could revolutionize the treatment of chronic pain. It could provide relief for millions of people without the risk of addiction or other serious side effects. However, much more research is needed before NFEPP can be approved for use in humans.

See Also

• Fentanyl
• Opioid
• Chronic pain
• Mu-opioid receptor

NFEPP Resources
Latest articles Most recent articles Ongoing trials	Wikipedia